Egg white trypsin inhibitor activated coagulase clotting when added to a final concentration between 2 and 60 mg/ml. The greatest increase in clotting rate was observed in reaction mixtures containing the lowest concentrations of serum and plasma. Maximal activation was reached with 40 mg of trypsin inhibitor per ml when either serum or plasma was used as the source of coagulase-reacting factor (CRF). The increased rate of clotting is partly due to inhibition of plasmin. Freezing and thawing reduced plasma clotting inhibition. Soybean trypsin inhibitor also activated the coagulase reaction. The increased rate of clotting was observed with a coagulase preparation from organisms which produced plasminogen activators and with the culture supernatant fraction from organisms which did not activate plasminogen to plasmin. The tube test for coagulase could be made more sensitive for some strains of staphylococci by increasing the concentration of CRF (added as plasma or serum) by adding trypsin inhibitor, or both.
The ability of certain staphylococci to clot blood plasma was first reported by Loeb in 1903 (10) . Coagulase was shown by Smith and Hale (14) to coagulate fibrinogen only in the presence of a third factor found in the plasma of certain animals (3) . This plasma factor was called coagulase-reacting factor (CRF) by Tager (15) .
The coagulase test is currently recognized as one of the best in vitro criteria for determining the potential pathogenicity of a staphylococcus. Although many variations of coagulase testing have been devised, i.e., the tube test, the plate test, and the serum soft agar test, all tests for free coagulase require a suitable plasma substrate. In 1908, Much showed that diluted plasma was often more satisfactory than the same plasma used full strength, due to dilution of plasma inhibitors (4) . The standard tube test for coagulase (5, 9) uses plasma diluted 1:3. The routine coagulase test has been found to be unable to detect small amounts of coagulase produced by certain strains of staphylococci. Sword et al. (C. P. Sword, T. Shikashio, M. G. Sword, and M. K. Martin, Bacteriol. Proc., p. 110, 1961) showed that several strains of staphylococci produced small amounts of coagulase which was demonstrable only after concentration procedures. These findings indicate the need for a more sensitive coagulase test.
Plasmin is a blood serum protease which interferes with the coagulase reaction (16) . Plasmin is inactivated by soybean trypsin inhibitor (13) .
It seemed likely that trypsin inhibitor could inactivate some of the plasma inhibitors referred to by Much. The purpose of this study was to determine if the coagulase assay system could be made more sensitive by adjusting the CRF level and adding trypsin inhibitor. All components of the reaction mixture were dialyzed for 8 hr at 4 C by using a "continuous-flow" system in which the above citrate buffer was continuously replenished at the rate of 150 ml/hr. This buffer was used for dilutions to minimize pH and ionic strength differences of the reaction components.
MATERIALS AND METHODS

Cultures
The reactants were maintained at 4 C or were frozen (-15 C) and thawed immediately before use. During the preparations for the tests, the clotting mixture components were maintained in an ice-water bath (0 C). Timing was started when each series of tubes was placed in the water bath (37 C). The tests were performed with a 1-ml reaction mixture in tubes (12 by 74 mm).
Determination of coagulase reaction velocity. Clotting times were determined at 1-min intervals by gently tipping the individual tubes. The extent of clotting was estimated (from negative to 4+) by the procedure of Turner and Schwartz (18) . When fibrin gel formation was noticed, readings were made at 0.5-min intervals until the tube containing the reaction mixture could be inverted without the fibrin gel being dislodged-a 4+ reaction.
The effect of egg white trypsin inhibitor (EWTI) on the rate of coagulase clotting was determined with EWTI concentrations from 0 to 60 mg/ml. The substrates were 10, 20, 30, and 40% plasma, or 10, 20, 30, and 40% serum + 10% plasma. All tubes contained 10% fibrinogen preparation, 10% coagulase suspension, and sufficient citrate buffer to bring the volume of the reaction mixture to 1 ml.
The reaction velocity data are presented by plotting the time taken to produce a 4+ fibrin gel as a function of serum or plasma concentration for each level of trypsin inhibitor used.
S. aureus 19095 coagulase clotting. S. aureus 19095 was inoculated into 100 ml of BHI broth in a 250-ml DeLong culture flask. The culture was incubated at 35 C for 48 hr on a rotary shaker at 210 rev/min. After growth, the cells were removed by centrifuging at 4,080 X g for 10 min.
The clarified supernatant (5 ml) was dialyzed against continuously flowing citrate buffer, and coagulase tests were performed with a 10% serum reaction mixture as described above. The extent of clotting was determined at 15-mnn intervals.
RESULTS
The effect of EWTI concentration on the clotting reaction with frozen and thawed plasma is shown in Fig. 1 . All concentrations of trypsin inhibitor used increased the rate of clotting over Figure 1 also shows that the increased plasma concentration resulted in more rapid clotting at each concentration of EWTI tested. The greatest increase was observed with the control, whereas the smallest increase was noted with 40 and 60 mg of EWTI per ml.
The effect of EWTI concentration on coagulase clotting with 10 to 40% rabbit serum (concentrated twofold) and 10% plasma is shown in Fig. 2 . All concentrations of EWTI tested activated coagulase clotting when serum was the principal source of CRF. The reaction velocities produced by 40 and 60 mg/ml were nearly identical; hence, maximal activation was reached with these concentrations using both serum and plasma. Figure 2 also shows that increased serum concentration allowed faster clotting at each concentration of EWTI tested. The fastest clotting observed with 1 mg of coagulase per ml in the reaction mixture was the production of a 4+ fibrin gel in 6.5 min with 40% serum and 40 mg of EWTI per ml. When 2 mg of coagulase per ml was used in this system, a firm gel was obtained in 5 min. Figure 3 illustrates the activation of coagulase clotting by EWTI by using fresh plasma. Since the increase in reaction rates produced by 40 and 60 mg of EWTI per ml were similar, the upper limit of activation was approached. At Plasmin is known to inactivate coagulase (16) . Staphylococcal Muller factor and staphylokinase are believed to activate plasminogen to plasmin (7, 17) . This enzyme has similar specificity to trypsin and is inactivated by trypsin inhibitor (13) . Kunitz and Northrop (8) suggested that one molecule of trypsin inhibitor reacts with one molecule of trypsin to form an addition compound. This linear relationship would be expected for plasmin inactivation. The inactivation of plasmin in coagulase studies is especially important in plasma and serum which have had plasminogen spontaneously activated or acted upon by the staphylococcal plasminogen activators.
Soybean trypsin inhibitor (SBTI) has been used in studying the esterase activity of coagulase preparations (2, 6) since it inhibits fibrinolysis by plasmin. In studying the esterase activity of activated coagulase on N' -toluene-p-sulfonyl-Larginine methyl ester, Haughton and Duthie (6) reported that activated coagulase was not detectably inhibited by 400 ,ug of SBTI per ml. In similar experiments, Drummond and Tager (2) used 0.4 mg of SBTI in a 0.3-ml reaction mixture and reported that their results confirmed the observations of Haughton and Duthie (6) . These investigators used SBTI at lower levels than the trypsin inhibitor concentrations employed in the experiments reported here.
Comparison of Fig. 1 and 3 with Fig. 2 reveals that concentrated serum increased the rate of reaction more than plasma. This difference was probably due to the approximately sixfold difference in CRF level between the concentrated serum and the plasma diluted 1:3.
Another difference noted between Fig. 1 and 2 is that the activation by EWTI appeared to be less for the serum than for the plasma. For example, the activation at 20% serum + 10% plasma was 2 min for an increase in EWTI from 2 to 60 mg/ml, and the activation at 20% plasma was 13 min for the same increase in trypsin inhibitor. This reduced activation with the serum source of CRF may reflect the fact that the maximal rate of fibrin gel formation was approached at the concentrations of reactants used, or that the serum contained higher levels of clotting inhibitors than the plasma. When the reaction mixture contained 1 mg of coagulase per ml, the maximal rate of clotting was obtained with 40 mg of EWTI per ml with serum or plasma.
The data plotted in Fig. 1 were obtained with plasma which had been frozen (-15 C) and thawed before use. When identical experiments were performed by using the same substrate before freezing, the rates of clotting with 40% plasma containing 10 to 60 mg of EWTI per ml were slower than those with 30% plasma. This decreased velocity at the highest level of CRF added was generally not observed when concentrated rabbit serum was used as the primary substrate. The freezing and thawing treatment may have reduced the inhibition observed with the 40% plasma.
The partially purified coagulase used in these experiments was prepared from S. aureus 265-1. This strain was a potent producer of both Muller factor and staphylokinase, and the coagulase preparation contained these plasminogen activators. To determine if the trypsin inhibitor activation of coagulase clotting was unique to Staphylococcus strains which produced these kinases, the dialyzed culture supernatant fraction from S. aureus 19095 was assayed with a 10% serum reaction mixture containing 0 to 60 mg of EWTI per ml. It was found that trypsin inhibitor nearly doubled the coagulase reaction rate for this strain.
The mechanism of activation by trypsin inhibitor is not known. It seems likely that the effect is partly due to the inhibition of plasmin; however, it appears that more than plasmin inhibition is involved since similar activation was observed with S. aureus strains which did and did not produce plasminogen activators.
The activation of coagulase clotting by trypsin inhibitor does not appear to involve a stoichiometric inactivation of plasmin by trypsin inhibitor. If only plasmin inactivation were involved, different concentrations of EWTI should have produced the maximal activation in the concentrated serum and the diluted plasma (due to the approximately sixfold difference in plasminogen concentration). This difference in levels of EWTI required to produce maximal activation in plasma and serum was not observed. Normal plasma has been found to contain between 2 and 6 mg of plasminogen per ml (12) . By using these figures for calculation, it was determined that the 40% concentrated serum reaction mixture would have contained a maximum of 4.8 mg of plasminogen per ml. This mixture contained approximately 80% of the plasmin (or precursors) present in normal serum. Since the potency of the trypsin inhibitor was known, it was calculated that maximal plasmin inhibition would be expected with 7 mg of EWTI per ml. Experiments showed that activation increased up to a concentration of 40 mg/ml. Trypsin inactivation by plasma trypsin inhibitor does not always follow a linear relationship in the presence of blood plasma (11 Preliminary studies indicate that SBTI and EWTI have a similar activating effect on the coagulase reaction. The activation by trypsin inhibitor appears to be greater with more dilute serum or plasma. This may be why previous reports (2, 6) failed to recognize the activating influence in reaction mixtures containing coagulase and purified CRF.
The tube coagulase test can be made more sensitive by manipulation of plasma or serum (CRF) and trypsin inhibitor concentrations. The results obtained with S. aureus 19095 illustrate how the addition of trypsin inhibitor to the coagulase test system may be useful in detecting low levels of coagulase. Thus, the use of this activator would allow coagulase detection with a 4-hr test period, whereas the conventional procedure would be unable to detect clotting activity in this time. There would be fewer incorrect "coagulase negative" reports. Although the diagnostic significance of the low coagulase producer has not been studied, the more sensitive assay system described here may provide a tool for further investigation.
